x
Filter:
Filters applied
- Commentary
- confidence intervalRemove confidence interval filter
- EGBRemove EGB filter
Publication Date
Please choose a date range between 2018 and 2018.
Author
- Alexandre, Marina1
- Avenel-Audran, Martine1
- Bara, Corina1
- Benichou, Jacques1
- Bernard, Philippe1
- Bernier, Claire1
- Bourgault-Villada, Isabelle1
- Chaby, Guillaume1
- Collet, Evelyne1
- D'Incan, Michel1
- Dereure, Olivier1
- Duvert-Lehembre, Sophie1
- Fardet, Laurence1
- Ferrier-Le-Bouedec, Marie-Christine1
- Hebert, Vivien1
- Ingen-Housz-Oro, Saskia1
- Jeudy, Geraldine1
- Joly, Pascal1
- Labeille, Bruno1
- Litrowski, Noémie1
- Mahe, Emmanuel1
- Morice, Cécile1
- Pauwels, Christine1
- Picard-Dahan, Catherine1
- Plaquevent, Marthe1
Pemphigus & Pemphigoid
1 Results
- Original Article Clinical Research: EpidemiologyOpen Archive
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Journal of Investigative DermatologyVol. 139Issue 4p835–841Published online: December 10, 2018- Marthe Plaquevent
- Florence Tétart
- Laurence Fardet
- Saskia Ingen-Housz-Oro
- Laurence Valeyrie-Allanore
- Philippe Bernard
- and others
Cited in Scopus: 56Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped.
